anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Vancomycin
Trial phase: Phase 3
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)

Vancomycin: vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
Eligibility criteria:
Inclusion Criteria:

Type 1 and Type 2 Diabetes mellitus
MRSA infected foot ulcus Wagner 1-2 without primary surgical intervention
Therapy duration will last at least more than 5 days
men and women age 18 - 80 years
Declaration of patient's consent
Ability and willingness to give written informed consent and to comply with the requirements of the study
Sexually active females, unless surgically sterile, must be willing to use 2 forms of contraception through the end of the study. Sexually active woman must, except if they were surgically sterilized, have to use for already 30 days before first dose of study medication an effective method of pregnancy prevention. Acceptable forms of contraception for female subjects include: oral, transdermal, injectable or implanted contraceptives, intrauterine device (IUD), female condom, diaphragm with spermicide, cervical cap, absolute waiver of sexual intercourse, use of a condom by the sexual partner, or sterile sexual partner. Male subjects with partners of child-bearing potential should use barrier contraception in addition to having their partners use another method of contraception.

Exclusion Criteria:

Osteomyelitis according to international consensus guideline (3 of 5 criteria apply for diagnosis)
Presence of a severe nephropathy (creatinine clearance < 30 ml/min)
Advanced diabetic retinopathy
Simultaneous participation in another study or participation in a study in the past 30 days
Non permissible concomitant medication e.g. therapy regimen using several antibiotics
Contraindication for antibiotics
Dialysis essential
Pregnancy (to be determined by pregnancy test) or unsafe contraception
Neutropenia
immunosuppression (oral immunosuppressives, Corticoids exaggerating 7.5 mg Prednisolon-equivalents)
Chronic liver disease (AST or ALT increased to 10fold, bilirubin increased to threefold compared to normal values)
Intervention: Ibuprofen
Trial phase: Phase 4
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: 800mg/8mL of intravenous ibuprofen over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3

ibuprofen intravenous: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
Eligibility criteria:
Inclusion Criteria:

Capable of providing informed consent
American Society Anesthesiologists (ASA) rating I-III
Subjects age 18-80 capable of providing consent.
Subjects undergoing electroconvulsive therapy using succinylcholine as the sole neuromuscular blocking agent.
Subjects who have scored ≥23 on the Mini-Mental State Examination.

Exclusion Criteria:

Subjects who have had a recent thrombotic event, myocardial infarction or stroke or episode of Congestive Heart Failure (CHF) within less than 3 months.
Subjects who have had a recent cardiovascular surgery within the last 3 months.
Subjects with active Gastrointestinal bleeding
Subjects who have asthma, itching or allergic type reaction following aspirin or other NSAID administration
Subjects with a known hypersensitivity to ibuprofen
Subjects with heart failure, bleeding disorders or kidney failure
Subjects taking aspirin, Angiotensin converting enzyme (ACE) inhibitors, or anticoagulants within one month.
Subjects with any devices used to treat pain (intrathecal pumps, spinal cord stimulators etc)
Subjects with a history of fibromyalgia or chronic myositis
Subjects who are pregnant
Subjects who do not have a phone
Subjects who have had previous ECT
Subjects receiving toradol (Ketorolac)
Subjects with reported renal disease within less than 3 months.
Subjects who have had previous electroconvulsive therapy within the last 3 months
Intervention: Micafungin
Trial phase: Phase 4
ATC code: J02AX05
SMILES: CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 58
Group description: This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).

micafungin: Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
Eligibility criteria:
Inclusion Criteria:

Subjects of greater than or equal to 18 years of age of either sex and of any race.

Disease definition:

Anticipated or documented prolonged neutropenia (ANC<500/mm3 [0.5x109/L]) at baseline or likely to develop within 3 to 5 days and lasting for at least 7 days due to:
Intensive induction chemotherapy for new diagnosis of acute myelogenous leukemia, acute lymphocytic leukemia or myelodysplastic syndrome receiving standard anthracycline based chemotherapy
Re-induction of acute myelogenous or lymphocytic leukemia after primary relapse
Myelodysplastic syndromes requiring induction (myelosuppressive) chemotherapy
Female subjects of childbearing potential must have a negative serum pregnancy test as per MSKCC guidelines.
Able to swallow oral medications

Exclusion Criteria:

Subjects with history of presumed or proven invasive fungal infection within 30 days of randomization.
Subjects who are taking the following:

Drugs known to interact with posaconazole and that may lead to life-threatening side effects (terfenadine, cisapride, and ebastine at entry or within 24 hours before entry, or astemizole at entry or within 10 days before entry); b. Drugs known to lower the serum concentration/efficacy of posaconazole: cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, and isoniazid at entry or within 24 hours before entry; c. Subjects who are planned to receive > 2mg flat dose of vinca alkaloids.

Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents.
Subjects with renal insufficiency (estimated creatinine clearance less than 20 mL/minute at baseline or likely to require dialysis during the study).
Subjects having an electrocardiogram with a prolonged QTc interval by manual reading: QTc greater than 490 msec.
Subjects with moderate or severe liver dysfunction at baseline, defined as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than 5 times the upper limit of normal (ULN), or a total bilirubin level greater than 3 times the ULN.
Subjects who are undergoing re-induction chemotherapy and have participated in this study during their first induction chemotherapy.
Subjects who will be receiving dasatinib.
Intervention: Posaconazole
Trial phase: Phase 4
ATC code: J02AC04
SMILES: CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 55
Group description: This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).

posaconazole: Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
Eligibility criteria:
Inclusion Criteria:

Subjects of greater than or equal to 18 years of age of either sex and of any race.

Disease definition:

Anticipated or documented prolonged neutropenia (ANC<500/mm3 [0.5x109/L]) at baseline or likely to develop within 3 to 5 days and lasting for at least 7 days due to:
Intensive induction chemotherapy for new diagnosis of acute myelogenous leukemia, acute lymphocytic leukemia or myelodysplastic syndrome receiving standard anthracycline based chemotherapy
Re-induction of acute myelogenous or lymphocytic leukemia after primary relapse
Myelodysplastic syndromes requiring induction (myelosuppressive) chemotherapy
Female subjects of childbearing potential must have a negative serum pregnancy test as per MSKCC guidelines.
Able to swallow oral medications

Exclusion Criteria:

Subjects with history of presumed or proven invasive fungal infection within 30 days of randomization.
Subjects who are taking the following:

Drugs known to interact with posaconazole and that may lead to life-threatening side effects (terfenadine, cisapride, and ebastine at entry or within 24 hours before entry, or astemizole at entry or within 10 days before entry); b. Drugs known to lower the serum concentration/efficacy of posaconazole: cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, and isoniazid at entry or within 24 hours before entry; c. Subjects who are planned to receive > 2mg flat dose of vinca alkaloids.

Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents.
Subjects with renal insufficiency (estimated creatinine clearance less than 20 mL/minute at baseline or likely to require dialysis during the study).
Subjects having an electrocardiogram with a prolonged QTc interval by manual reading: QTc greater than 490 msec.
Subjects with moderate or severe liver dysfunction at baseline, defined as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than 5 times the upper limit of normal (ULN), or a total bilirubin level greater than 3 times the ULN.
Subjects who are undergoing re-induction chemotherapy and have participated in this study during their first induction chemotherapy.
Subjects who will be receiving dasatinib.
Intervention: Propofol
Trial phase: Not Applicable
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Subjects will be sedated with propofol.

propofol: Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
Eligibility criteria:
Inclusion Criteria:

ASA I-III.
Scheduled for DBS.

Exclusion Criteria:

History of dystonia.
Severe heart failure with ejection fraction less than 30%.
History of obstructive sleep apnea.
History of renal failure with creatinine level > 2 mg/dl.
Allergies to α-2 agonists and propofol.
Current use of α-2 agonist medications such as clonidine.
Intervention: 4-((2R)-4-tert-Butylpiperazine-2-carbonyl)-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide
Trial phase: Phase 2
SMILES: CC(C)(C)N1CCNC(C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(F)c3)CC2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: AZD2423 : 3x50 mg tablet once daily in the morning
Eligibility criteria:
Inclusion Criteria:

Provision of signed informed consent form
Males and female patients aged 18 to 80 years
Patients with neuropathic pain due to peripheral nerve injury caused by trauma or surgery

Exclusion Criteria:

Other paint that may confound assessment of neuropathic pain
History of treatment failure with more than three adequate trials of treatment for neuropathic pain
Central neuropathic pain conditions (caused by Central Nervous System injury/disease, eg. Stroke)
Intervention: 4-((2R)-4-tert-Butylpiperazine-2-carbonyl)-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide
Trial phase: Phase 2
SMILES: CC(C)(C)N1CCNC(C(=O)N2CCN(C(=O)Nc3ccc(Cl)c(F)c3)CC2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 48
Group description: AZD2423 : 1x20 mg tablet once daily in the morning
Eligibility criteria:
Inclusion Criteria:

Provision of signed informed consent form
Males and female patients aged 18 to 80 years
Patients with neuropathic pain due to peripheral nerve injury caused by trauma or surgery

Exclusion Criteria:

Other paint that may confound assessment of neuropathic pain
History of treatment failure with more than three adequate trials of treatment for neuropathic pain
Central neuropathic pain conditions (caused by Central Nervous System injury/disease, eg. Stroke)
Intervention: MEGESTROL ACETATE
Trial phase: Phase 2
ATC code: G03AA04 | G03AB01 | G03AC05 | G03DB02 | G03FA08 | G03FB04 | L02AB01
SMILES: [H][C@@]12C=C(C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Any pediatric patient with an underlying diagnosis of a malignancy (excluding hematological malignancies like leukemias and lymphomas)
≥5% weight loss from diagnosis of primary malignancy (must be currently on chemotherapy and/or radiation therapy or scheduled to receive cancer therapy OR ≥5% weight loss following bone marrow transplant (autologous or allogeneic blood/bone marrow) and not actively receiving corticosteroid therapy
Negative pregnancy test done =< 7 days prior to registration for women of childbearing potential only

Exclusion Criteria:

Receiving tube feedings or parenteral nutrition
Evidence of ascites
Current (within the past 28 days) or planned treatment with adrenal steroids (short-term use of dexamethasone around days of intravenous chemotherapy is allowed for protection against emesis), androgens, progestational agents, or appetite stimulants (e.g., dronabinol)
Known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting (> 5 episodes/week)
History of unresectable brain tumor or cancer metastatic to the brain
History of thromboembolic disease
Insulin-requiring diabetes
Congestive heart failure and/or uncontrolled hypertension
Anticoagulation
Previous history of thrombosis (personal and immediate family)
Concurrent corticosteroid therapy (except as an antiemetic)
Intervention: Prasugrel
Trial phase: Phase 4
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 65
Group description: All participants who received prasugrel
Eligibility criteria:
Inclusion Criteria:

Patients with angiographically documented coronary artery disease.
Age between 18 to 74 years
On treatment with prasugrel 10mg/daily for at least 14 days.

Exclusion Criteria:

Blood dyscrasias or bleeding diathesis
Antiplatelet treatment with clopidogrel or ticlopidine
Recent antiplatelet treatment (< 14 days) with a glycoprotein IIb/IIIa antagonist
Platelet count <100x106/µL
Active bleeding or hemodynamic instability.
Unstable angina, acute or recent (<14 days) myocardial infarction.
Serum creatinine >2 mg/dL
Baseline ALT >2.5 times the upper limit of normal
Oral anticoagulation with a coumarin derivative
History of stroke, TIA or intracranial bleeding
Weight <60kg
Pregnant females
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Patients with type 2 DM on aspirin therapy will undergo treatment with escalating aspirin doses. Patients modified their aspirin regimen on a weekly basis according to the following scheme: 81mg/od. 81mg/bid, 162 mg/od, 162 mg/bid, 325mg/od.
Eligibility criteria:
Inclusion Criteria:

Medically treated (taking oral hypoglycemic medication and/or insulin) type 2 diabetes mellitus patients between 18 to 75 years with stable coronary artery disease

Exclusion Criteria:

Blood dyscrasia or bleeding diathesis
Oral anticoagulation therapy with a coumadin derivative
Recent antiplatelet treatment (< 30 days) with a glycoprotein IIb/IIIa antagonist, thienopyridine (ticlopidine, clopidogrel), cilostazol or dipyridamole Platelet count < 100 /microL
History of gastrointestinal bleed within last 6 months
History of cerebrovascular accident within last 3 months
History of hospitalization for an acute coronary event or coronary revascularization (percutaneous or surgical) in the past 12 months
Active bleeding or hemodynamic instability
Any active malignancy
Serum creatinine > 2 mg/dL
Baseline ALT > 2.5 times the upper limit of normal
Pregnant females
HbA1C > 10%
Use of nonsteroidal anti-inflammatory drugs past 10 days.
Intervention: PREDNISOLONE ACETATE
Trial phase: Phase 3
SMILES: CC(=O)OCC(=O)C1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3C(O)CC21C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 54
Group description: Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period
Eligibility criteria:
Inclusion Criteria:

Diagnosis of endogenous anterior uveitis in at least 1 eye.
The presence of > 10 cells in the anterior chamber of at least one eye, and a flare score of > 2 in that same eye.
Age 2 years or older on day of consent.
Negative urine pregnancy test on Day 0 for females of childbearing potential who are not at least 1 year post-menopausal or surgically sterilized.
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Presence of endogenous anterior uveitis diagnosed for > 2 weeks prior to enrollment in the study.
Presence of intermediate uveitis, posterior uveitis or panuveitis in either eye.
Instillation of any topical corticosteroid or NSAID in the study eye within 7 days of instillation of study drug.
History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an IOP ≥ 21 millimeters mercury in either eye.
History of steroid-induced elevation of intraocular pressure.
Any confirmed or suspected active viral, bacterial or fungal keratoconjunctival disease in either eye.
History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an intraocular pressure (IOP) > 21 mmHg in either eye.
Corneal abrasion or ulceration in either eye.
Pregnancy or lactation.
Other protocol-defined exclusion criteria may apply.
Intervention: Desflurane
Trial phase: Not Applicable
ATC code: N01AB07
SMILES: FC(F)OC(F)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Administration of Desflurane
Eligibility criteria:
Inclusion Criteria:

Age 18-65
Female patients undergoing outpatient gynecologic and breast surgery
Under general anesthesia using an LMA
ASA I,II,

Exclusion Criteria:

Patients on CNS depressants
Chronic opioid use
Corticosteroid
Pregnant patients
Full stomach
Morbidly obese (BMI >35kg/m2)
Hepatitis B
Hepatitis C
Coronary artery disease
Liver disease
Renal disease
Seizure disorder

Dropout criteria:

Need for endotracheal tube
Surgeon or patient request
Hospital admission
Intervention: Indacaterol
Trial phase: Phase 3
ATC code: R03AC18 | R03AK14 | R03AL04 | R03AL12
SMILES: CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 476
Group description: QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Eligibility criteria:
Inclusion Criteria:

Male or female adults aged ≥40 yrs
Smoking history of at least 10 pack years
Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008)
Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) <70%

Exclusion Criteria:

Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1
Patients with concomitant pulmonary disease
Patients with a history of asthma
Any patient with lung cancer or a history of lung cancer
Patients with a history of certain cardiovascular co-morbid conditions
Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
Patients in the active phase of a supervised pulmonary rehabilitation program
Patients contraindicated for inhaled anticholinergic agents and β2 agonists
Other protocol-defined inclusion/exclusion criteria may apply
Intervention: Tiotropium
Trial phase: Phase 3
ATC code: R03AL06 | R03AL10 | R03BB04 | R03BB54
SMILES: [H][C@]1(OC(=O)C(O)(c2cccs2)c2cccs2)C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@]([H])(C1)[N+]2(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 480
Group description: Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Eligibility criteria:
Inclusion Criteria:

Male or female adults aged ≥40 yrs
Smoking history of at least 10 pack years
Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008)
Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) <70%

Exclusion Criteria:

Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1
Patients with concomitant pulmonary disease
Patients with a history of asthma
Any patient with lung cancer or a history of lung cancer
Patients with a history of certain cardiovascular co-morbid conditions
Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
Patients in the active phase of a supervised pulmonary rehabilitation program
Patients contraindicated for inhaled anticholinergic agents and β2 agonists
Other protocol-defined inclusion/exclusion criteria may apply
Intervention: Ephedrine
Trial phase: Phase 4
ATC code: A08AA56 | C01CA26 | R01AA03 | R01AB05 | R01BA02 | R01BA52 | R03CA02 | S01FB02
SMILES: CN[C@@H](C)[C@@H](O)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 593
Group description: Mucinex D (1200 mg GGE and 120 mg pseudoephedrine HCl extended release bilayer tablet bid with a full glass of water for 7 days
Eligibility criteria:
Inclusion Criteria:

patients aged 18 to 75 yrs of age presenting at a clinical site with symptoms diagnostic for an acute upper respiratory tract infection within the last 5 days

Exclusion Criteria:

patients who had chronic, recurring respiratory signs and symptoms due to conditions such as chronic allergic rhinitis, chronic sinusitis or chronic bronchitis which in the investigator's opinion, confounded interpretation of symptom ratings for the acute upper respiratory infection. Also excluded were patients with a fever greater than 101 degrees F.